| 1. |
趙嵐, 楊烽華, 張少衡. 腫瘤心臟病學及抗腫瘤藥物的心臟毒性. 生理科學進展, 2017, 48(3): 197-202.
|
| 2. |
Francis SA, Asnani A, Neilan T, et al. Optimizing cardio-oncology programs for cancer patients. Future Oncol, 2015, 11(14): 2011-2015.
|
| 3. |
Bellinger AM, Arteaga CL, Force T, et al. Cardio-oncology: how new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation, 2015, 132(23): 2248-2258.
|
| 4. |
Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol, 2014, 64(9): 938-945.
|
| 5. |
Zamorano JL, Lancellotti P, Rodriguez Mu?oz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur Heart J, 2016, 37(36): 2768-2801.
|
| 6. |
隋道敬, 馮曉敬, 徐慧. 保心康預防阿霉素為主化療方案導致心臟毒性 60 例臨床研究. 中醫雜志, 2004, 45(4): 272-273.
|
| 7. |
代國華, 陳明媚. 穩心顆粒干預蒽環類抗腫瘤藥物引起心律失常的臨床觀察. 亞太傳統醫藥, 2011, 7(3): 59-60.
|
| 8. |
周愛民. 穩心顆粒治療蒽環類抗腫瘤藥物誘發的心律失常的臨床療效觀察. 腫瘤藥學, 2011, 1(6): 535-537.
|
| 9. |
劉紅梅, 劉世專, 黃衛俊, 等. 穩心顆粒在乳腺癌蒽環類化療引起心臟毒性患者中的應用及預后. 中國現代藥物應用, 2017, 11(8): 123-124.
|
| 10. |
Patanè S. Cardiotoxicity: anthracyclines and long term cancer survivors. Int J Cardiol, 2014, 176(3): 1326-1328.
|
| 11. |
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention rehabilitation (EACPR). Eur Heart J, 2016, 37(29): 2315-2381.
|
| 12. |
Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol, 2002, 20(5): 1215-1221.
|
| 13. |
鄭夢穎, 陳曉品. 化療藥物對重要臟器不良反應的研究進展. 重慶醫學, 2012, (14): 1431-1433.
|
| 14. |
中國臨床腫瘤學會中華醫學會血液學分會. 蒽環類藥物心臟毒性防治指南 (2013 年版). 臨床腫瘤學雜志, 2013, 18(10): 925-934.
|
| 15. |
蔡亞紅, 唐方明. 蒽環類藥物的心臟毒性預防措施研究進展. 新鄉醫學院學報, 2018, (3): 244-247.
|
| 16. |
Stěrba M, Popelová O, Vávrová A, et al. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal, 2013, 18(8): 899-929.
|
| 17. |
Fulbright JM, Egas-Bejar DE, Huh WW, et al. Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy. Cancer Chemother Pharmacol, 2015, 76(6): 1297-1307.
|
| 18. |
Barry E, Alvarez JA, Scully RE, et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother, 2007, 8(8): 1039-1058.
|
| 19. |
沈映君. 中藥藥理學. 上海: 上海科學技術出版社, 2007: 162-163.
|
| 20. |
楊從信, 余群. 甘松整律湯治療室性早搏 35 例療效觀察. 云南中醫學院學報, 2000, 23(1): 32-33.
|
| 21. |
陳鵬. 步長穩心顆粒治療冠心病合并心律失常臨床觀察. 生物磁學, 2005, 5(2): 21-22.
|
| 22. |
中國生物醫學工程學會心臟起搏與電生理分會, 中華醫學會心血管病學分會, 中華心血管病雜志編輯委員會, 等. 胺碘酮抗心律失常治療應用指南. 中華心血管病雜志, 2006, 32(12): 1065-1071.
|
| 23. |
王浴生, 鄧文龍, 薛春生, 主編. 中藥藥理與應用 (第 2 版). 北京: 人民衛生出版社, 1994: 38, 192-193, 429, 986.
|